MDM2 Copy Numbers in Well Differentiated and Dedifferentiated Liposarcoma: Where Do We Draw the Line?

被引：0
|
作者：
Ware, P. [1 ]
Snow, A. [1 ]
Pettenati, M. [1 ]
Qasem, S. [1 ]
机构：
[1] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA
来源：
MODERN PATHOLOGY | 2012年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
82
引用
收藏
页码：22A / 22A
页数：1
相关论文
共 50 条
  • [1] MDM2 Copy Numbers in Well Differentiated and Dedifferentiated Liposarcoma: Where Do We Draw the Line?
    Ware, P.
    Snow, A.
    Pettenati, M.
    Qasem, S.
    LABORATORY INVESTIGATION, 2012, 92 : 22A - 22A
  • [2] MDM2 Copy Numbers in Well-Differentiated and Dedifferentiated Liposarcoma
    Ware, Patrick L.
    Snow, Anthony N.
    Gvalani, Maya
    Pettenati, Mark J.
    Qasem, Shadi A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (03) : 334 - 341
  • [3] Prognostic impact of the MDM2/HMGA2 ratio and clinicopathological factors in well-differentiated and dedifferentiated liposarcoma
    Yamashita, Kyoko
    Kohashi, Kenichi
    Yamada, Yuichi
    Akatsuka, Shinya
    Oda, Yoshinao
    MODERN PATHOLOGY, 2019, 32
  • [4] Prognostic impact of the MDM2/HMGA2 ratio and clinicopathological factors in well-differentiated and dedifferentiated liposarcoma
    Yamashita, Kyoko
    Kohashi, Kenichi
    Yamada, Yuichi
    Akatsuka, Shinya
    Oda, Yoshinao
    LABORATORY INVESTIGATION, 2019, 99
  • [5] Dedifferentiated melanoma with MDM2 gene amplification mimicking dedifferentiated liposarcoma
    Yousef, Samer
    Joy, Christopher
    Velaiutham, Shanta
    Maclean, Fiona M.
    Harraway, James
    Gill, Anthony J.
    Vargas, Ana Cristina
    PATHOLOGY, 2022, 54 (03) : 371 - 374
  • [6] Tumour histology and primary site but not MDM2 amplification levels are prognostic for clinical outcomes in well differentiated and dedifferentiated liposarcoma
    Chew, W. H. W.
    Chan, J. Y.
    Goh, W. L.
    Lim, J. H. C.
    Tan, S. H.
    Somasundaram, N.
    Poon, E. Y. L.
    Lim, A. S. T.
    Tan, M. H.
    Soo, K. C.
    Teo, M.
    Tay, T. K. Y.
    Selvarajan, S.
    Sittampalam, K.
    Quek, R.
    ANNALS OF ONCOLOGY, 2017, 28 : 150 - 150
  • [7] The novel role of MDM2 in the diagnosis and treatment of dedifferentiated liposarcoma
    Ichikawa, Jiro
    Kawasaki, Tomonori
    Onohara, Kojiro
    Kanno, Satoshi
    Wako, Masanori
    Ochiai, Satoshi
    Aoki, Kaoru
    Haro, Hirotaka
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [8] Where do we draw the line?
    Gornall, Jonathan
    BRITISH MEDICAL JOURNAL, 2007, 334 (7588): : 285 - 289
  • [9] TREATING DIFFERENTIATED THYROID-CARCINOMA - WHERE DO WE DRAW THE LINE
    MAZZAFERRI, EL
    MAYO CLINIC PROCEEDINGS, 1991, 66 (01) : 105 - 111
  • [10] Relevance of FNCLCC Grade and MDM2 Amplification Levels in Dedifferentiated Liposarcoma
    Jour, G.
    Gullett, A.
    Liu, M.
    Hoch, B. L.
    MODERN PATHOLOGY, 2014, 27 : 19A - 19A
12345